These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9738783)

  • 1. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
    Lebwohl M; Ellis C; Gottlieb A; Koo J; Krueger G; Linden K; Shupack J; Weinstein G
    J Am Acad Dermatol; 1998 Sep; 39(3):464-75. PubMed ID: 9738783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine: what clinicians need to know.
    Koo J; Lee J
    Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.
    Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA;
    G Ital Dermatol Venereol; 2014 Oct; 149(5):607-25. PubMed ID: 25213388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with Neoral.
    Shupack JL
    Int J Dermatol; 1997 Dec; 36 Suppl 1():34-6. PubMed ID: 9466220
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of psoriasis. Part 2. Systemic therapies.
    Lebwohl M; Ali S
    J Am Acad Dermatol; 2001 Nov; 45(5):649-61; quiz 662-4. PubMed ID: 11606913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
    Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
    J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cancer with cyclosporine in psoriasis.
    Arellano F
    Int J Dermatol; 1997 Dec; 36 Suppl 1():15-7. PubMed ID: 9466216
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
    Rosmarin DM; Lebwohl M; Elewski BE; Gottlieb AB;
    J Am Acad Dermatol; 2010 May; 62(5):838-53. PubMed ID: 19932926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin in psoriasis: how?
    Feldman SR; Garton R
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):250-3. PubMed ID: 15096128
    [No Abstract]   [Full Text] [Related]  

  • 12. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective.
    Griffiths CE; Voorhees JJ
    J Invest Dermatol; 1990 Nov; 95(5 Suppl):53S-55S. PubMed ID: 16788634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cyclosporine and severe psoriasis].
    Mazer JM
    Ann Dermatol Venereol; 1996; 123(4):280-4. PubMed ID: 8763757
    [No Abstract]   [Full Text] [Related]  

  • 15. Hair darkening after treatment with cyclosporin in a patient with psoriasis.
    Sadighha A; Zahed GM
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(10):1239-41. PubMed ID: 18331307
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
    Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA
    G Ital Dermatol Venereol; 2016 Aug; 151(4):432-5. PubMed ID: 25786483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciclosporin in psoriasis clinical practice: an international consensus statement.
    Griffiths CE; Dubertret L; Ellis CN; Finlay AY; Finzi AF; Ho VC; Johnston A; Katsambas A; Lison AE; Naeyaert JM; Nakagawa H; Paul C; Vanaclocha F
    Br J Dermatol; 2004 May; 150 Suppl 67():11-23. PubMed ID: 15115441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.
    Di Nuzzo S; Zanni M; De Panfilis G
    J Drugs Dermatol; 2007 Oct; 6(10):1046-7. PubMed ID: 17966184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.
    Cohen Barak E; Kerner M; Rozenman D; Ziv M
    Dermatol Ther; 2015; 28(3):126-30. PubMed ID: 25640261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of psoriasis treatment on genital warts: a case report.
    Campoli M; Cinotti E; Fimiani M; Pellegrino M; Tognetti L; Rubegni P
    Int J STD AIDS; 2019 Jul; 30(8):828-830. PubMed ID: 31106706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.